New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 14, 2014
12:47 EDTVRX, AGNAllergan slides question Valeant growth, disclosures, says BMO Capital
BMO Capital says Allergan (AGN) issued new slides today calling into question Valeant's (VRX) disclosures and growth. The firm finds the slides "interesting," and says Allergan management last week noted that its current business "has never been stronger." BMO thinks investors should own Allergan, and sees the upcoming Q2 results as a potential catalyst. The firm has an Outperform rating on the name with a $202 price target.
News For AGN;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 28, 2015
09:24 EDTVRXJefferies sees Pharma M&A continuing, lists 22 possible targets
Jefferies analyst David Steinberg believes the M&A wave in the Pharmaceuticals space that began in 2005 can continue as the key drivers remain largely intact. In a note titled "Who is Next? The Feeding Frenzy in Specialty Pharmaceuticals," Steinberg sees deals continuing amid cheap debt, the push for lower corporate taxes and investors rewarding many acquirers for their transactions. He points out there are now around 100 publicly traded Specialty Pharmaceutical companies following the recent life sciences IPO boom. Potential takeover targets, according to Steinberg, include Valeant (VRX), Shire (SHPG), Perrigo (PRGO), Zoetis (ZTS), Mallinckrodt (MNK), Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Pacira (PCRX), Indivior, Insys Therapeutics (INSY), The Medicines Co. (MDCO), Depomed (DEPO), Spectrum (SPPI), KYTHERA (KYTH), Revance (RVNC), XenoPort (XNPT), Mylan (MYL), Akorn (AKRX), Impax (IPXL), Amphastar Pharmaceuticals (AMPH), Anacor (ANAC) and BioDelivery Sciences (BDSI).
07:09 EDTVRXBioDelivery Sciences makes management changes to support Bunavail launch
Subscribe for More Information
May 27, 2015
19:14 EDTVRXOn The Fly: After Hours Movers
Subscribe for More Information
18:27 EDTVRXSalix receives FDA Approval of Xifaxan for treatment of IBS-D
Subscribe for More Information
16:59 EDTVRXFDA approves Salix-marketed Xifaxan
The FDA approved Viberzi and Xifaxan, two new treatments, manufactured by two different companies, for irritable bowel syndrome with diarrhea, or IBS-D, in adult men and women. Xifaxan is marketed by Salix Pharmaceuticals, which was acquired by Valeant Pharmaceuticals. Reference Link
May 21, 2015
19:54 EDTVRXValeant to expand Canadian presence in coming years, Globe and Mail says
Subscribe for More Information
May 20, 2015
06:37 EDTVRXSources: Valeant in talks to buy Amoun Pharmaceutical, Bloomberg reports
Subscribe for More Information
06:32 EDTVRXValeant CEO sees quintupling in Asia sales by 2020, Reuters reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use